Calcinerin Inhibitors Market is Predicted to See Growth Due to Increase in Organ Transplant Procedures
Calcineurin inhibitors such as cyclosporine and tacrolimus have been extensively used for immunosuppression in organ transplant recipients. The increasing number of organ transplant surgeries being performed globally is anticipated to drive demand for calcinerin inhibitors. Calinerin inhibitors help prevent the body's immune system from attacking and rejecting the transplanted organ which improves organ viability and patient survival rates. With the rising prevalence of chronic diseases resulting in organ failure and shortage of donor organs, calcinerin inhibitors play a crucial role in organ transplant management.
The global calcinerin inhibitor market is estimated to be valued at US$ 10.07 billion in 2024 and is expected to exhibit a CAGR of 10% over the forecast period of 2023 to 2030.
Key Takeaways
Key players operating in the calcinerin inhibitor market are Novartis AG, Amgen, F. Hoffmann-La Roche Ltd, Pfizer Inc., Incyte Corporation, Chiesi Farmaceutici S.p.A., Astellas Pharma Inc., Sanofi SA, Bristol Myers Squibb Company, Mylan N.V., Dr. Reddy's Laboratories Ltd., Senju Pharmaceutical Co. Ltd, Abbott, Lupin Limited, and Vibcare Pharma Pvt. Ltd. These players are focusing on expanding their footprint in emerging markets through partnerships and collaborations to cater to the rising demand.
The key opportunities in the market include development of next generation calcinerin inhibitors with improved safety profiles and less potential for nephrotoxicity or neurotoxicity. This would help increase eligibility criteria for organ recipients and drive broader market adoption.
Globally, emerging economies are expected to drive future growth opportunities for players. Factors such as rising per capita healthcare spends, growing medical tourism, and improving accessibility of organ transplants are expected to increase the uptake of calcinerin inhibitors in regions such as Asia Pacific, Latin America, and Middle East and Africa.
Market Drivers
The increase in geriatric population globally is expected to drive the growth of the calcineurin inhibitor market during the forecast period. Older adults aged 65 years and above are more susceptible to developing chronic illnesses such as cardiovascular disease, cancer, and diabetes which may result in organ failures. Calcineurin inhibitors will continue to be the standard of care for this patient cohort undergoing organ transplant procedures.
Market Restrains
The high cost of calcineurin inhibitors can limit their adoption in certain lower income countries and burden public payers. The average costs of drugs under calcineurin inhibitors category range from $10,000 to $25,000 per patient annually. These costs pose affordability challenges warranting development of more affordable generic and biosimilar versions to expand access.
Segment Analysis
The calcineurin inhibitor market is dominated by the cyclosporine segment. Cyclosporine is commonly used as an immunosuppressive drug after organ transplantation to prevent transplant rejection. It helps modulate the immune system by inhibiting T-cell activation. Cyclosporine effectively inhibits the action of calcineurin, a calcium-dependent phosphatase enzyme that is required for the initiation of T-cell immune response. Lower rejection rates and better graft survival outcomes have made cyclosporine the gold standard for post-transplant immunosuppressive therapy.
Global Analysis
North America currently holds the largest share in the calcineurin inhibitor market and is expected to continue dominating during the forecast period as well. The major factors driving the market growth in North America include the growing prevalence of autoimmune disorders, rising transplant procedures, and availability of advanced healthcare facilities. Europe holds the second position in terms of revenue share owing to the increasing research activities for developing novel treatment options along with government support for orphan drugs. The Asia Pacific is anticipated to showcase the fastest growth rate over the coming years due to improving healthcare infrastructure, increasing healthcare expenditures, and expanding patient pool.
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Romaian